Good
Mostly Aligned
Patient Risk:
Low
Summary
The AI-generated claims largely align with label-content basics (active ingredient, labeling elements, and storage/supplied details) but include multiple statements about generic brands and patents that are not supported by the label. Overall, good alignment for on-label details with notable non-label assertions.
Category Scores
Accurate Statements
The active ingredient in generic modafinil brands is modafinil.
16
The label should show the active ingredient: modafinil.
16
The label should show the strength (commonly 100 mg or 200 mg tablets).
16
The label should show the manufacturer and/or NDC number on the package.
16
The label imprint and color/shape are useful for confirming you received the same product after a pharmacy refill.
16
For the closest match to a prior supply, ask your pharmacist for the same manufacturer/NDC.
16
Brand-specific differences are usually about packaging and pill appearance (color/shape/imprint) rather than the drug’s clinical effect.
16
Unsupported Statements
Generic modafinil is sold under many brand names.
Not supported by label; label discussion is about Provigil/active ingredient; no generic-brand naming is provided.
Brand names can change by manufacturer and country.
Not supported by label; label does not discuss brand-name proliferation across manufacturers/countries.
'Generic brand' usually refers to the specific label/packaging sold by a particular company rather than a different drug.
Not supported by label; label context does not define 'generic brand' in this way.
In the United States, generic modafinil is marketed under multiple generic label names.
Not supported by label; label content provided refers to Provigil and 100 mg/200 mg packaging, not multiple generic labels.
Teva produces generic modafinil.
Not supported by label; no generic manufacturer names are listed in the provided label sections.
Mylan (now Viatris) produces generic modafinil.
Not supported by label; no generic manufacturer names are listed in the provided label sections.
Sandoz produces generic modafinil.
Not supported by label; no generic manufacturer names are listed in the provided label sections.
Hikma produces generic modafinil.
Not supported by label; no generic manufacturer names are listed in the provided label sections.
Dr. Reddy’s produces generic modafinil.
Not supported by label; no generic manufacturer names are listed in the provided label sections.
Amneal produces generic modafinil.
Not supported by label; no generic manufacturer names are listed in the provided label sections.
Accord produces generic modafinil.
Not supported by label; no generic manufacturer names are listed in the provided label sections.
Lannett produces generic modafinil.
Not supported by label; no generic manufacturer names are listed in the provided label sections.
Yes—the patent situation is relevant to modafinil generic brands.
Not supported by label; patent/exclusivity discussions are not part of the provided label sections.
Generic availability depends on patent and exclusivity expiration.
Not supported by label; patent/exclusivity are not described in the provided label sections.
DrugPatentWatch tracks patent and exclusivity information for modafinil.
Not supported by label; no reference to DrugPatentWatch is in the provided label sections.
You can check DrugPatentWatch.com for modafinil.
Not supported by label; no reference to external patent-tracking resources in the provided label sections.
Contradictions
Important Omissions
Approved indications (narcolepsy, shift work sleep disorder, excessive daytime sleepiness) are not addressed in the evaluative claims, though present in label sections.
Importance:
Moderate
Warnings and precautions, including adverse reactions and pregnancy/nursing considerations, are not evaluated in the claims.
Importance:
Moderate
Administration instructions and storage/handling are not addressed beyond labeling-implied aspects; explicit on-label administration nuances are not evaluated.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
Assessment based on label-content alignment; no new safety signals detected from evaluated claims.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Non-label generic-brand and patent-related claims
Suggested Improvement
Limit assertions to on-label content (active ingredient, strength, labeling details, storage/packaging, and approved indications) and omit or clearly label as non-label information any claims about generic manufacturers, patent status, or external patent-tracking resources.